Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal cancers can be associated with significant complications. Randomized trials have demonstrated increased morbidity with liberal fluid regimens in abdominal surgery.
C ytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as an important treatment modality for both primary and secondary peritoneal surface cancers. The CRS/HIPEC treatment involves peritonectomy procedures that often are accompanied by visceral organ resections and intestinal anastomoses, followed by perfusion of chemotherapy at 42°C.
1,2 Even at highvolume centers, CRS/HIPEC can be associated with major morbidity in greater than 50% of patients across a variety of organ systems. 3 This morbidity is multifactorial, as it is affected by patient demographics, tumor biology, and extent of treatment. 3, 4 Liberal perioperative fluid management often results in whole body fluid overload, leading to edema, 5 which can have a negative clinical effect on various organ systems. [5] [6] [7] Randomized trials have demonstrated decreased perioperative morbidity with restrictive fluid regimens in major abdominal surgery. 8, 9 In addition, these restrictive fluid regimens in the setting of goal-directed therapy and/or enhanced recovery after surgery pathways have been associated with improved clinical outcomes. [10] [11] [12] [13] [14] Yet, definitions of restrictive and liberal remain heterogeneous among studies in the literature. 15, 16 To our knowledge, optimal intraoperative fluid management practices in CRS/HIPEC have yet to be defined. As such, we sought to investigate the association between intraoperative fluid administration and morbidity in patients undergoing CRS/HIPEC at City of Hope National Medical Center, Duarte, California, a National Cancer Institute-designated comprehensive cancer center. We hypothesized that increased intraoperative fluid administration would be an independent predictor of increased overall morbidity.
Methods
Patients who underwent CRS/HIPEC from April 15, 2009 , to June 23, 2016 , were identified retrospectively from a prospectively collected database at City of Hope National Medical Center. Patients with complete data on intraoperative fluid administration were identified. Anesthetic approaches to fluid resuscitation and blood loss were not standardized. However, in general, blood was replaced with crystalloid at a 3:1 ratio and colloid at a 1:1 ratio, with transfusions administered for hemoglobin levels of 7.0 g/dL or lower or 10.0 g/dL or lower (to convert to grams per liter, multiply by 10) in patients with a significant cardiac history. All transfusion decisions were discussed between the anesthesiologist and attending surgeon.
The City of Hope National Medical Center Institutional Review Board granted a waiver of informed consent. Data were deidentified.
Collected preoperative data included patient sex, age, weight, and American Society of Anesthesiologists (ASA) physical status classification. The ASA classifications are from I to VI. Within the cohort of this study, the lowest classification was ASA II, defined as "a patient with mild systemic disease"; the highest classification, ASA IV, was defined as "a patient with severe systemic disease that is a constant threat to life." 17 Intraoperative variables collected included intravenous fluid volume, transfusion of blood products, estimated blood loss, urine output, operative time, number of anastomoses, peritoneal cancer index, and the chemotherapeutic agent administered. The peritoneal cancer index is calculated intraoperatively to assess the extent of peritoneal disease in the 13 regions of the peritoneal cavity. The score ranges from 0 (no tumor visualized) to 39 (lesions >5 cm and/or layering or confluence of multiple small tumor nodules in all 13 regions). 18 Intraoperative fluid (IOF) administration was calculated by combining crystalloid, colloid, and blood products and converted to a fluid rate (milliliters per kilogram per hour) as previously described. 19 The IOF rate allowed us to control for variables of patient weight and operative time, the latter of which could reflect the extent of surgery.
Statistical Analysis
Both the highest Clavien-Dindo classification and comprehensive complication index (CCI) were calculated for each patient to assess overall perioperative morbidity. The ClavienDindo classification is a validated ranking system to evaluate surgical complications, ranging from I (any deviation from the normal postoperative course without the need for pharmacologic treatment or surgical, endoscopic, and radiologic interventions) to V (death of a patient). Typically, major complications are referred to as IIIa (intervention not under general anesthesia). 20 The CCI uses a formula combining all perioperative complications and their severities into a continuous variable from 0 to 100 in each patient. 21 Adjusting for interacting variables, stepwise linear regression analyses were performed, with the CCI as the outcome variable. Statistical significance was accepted at P < .05. Statistical analysis was performed with Stata/MP, version 14 (StataCorp).
Results
A total of 133 patients who underwent CRS/HIPEC were identified, with 51 (38.3%) and 50 (37.6%) having diagnoses of metastatic appendiceal and colorectal cancers, respectively. Other primary cancers included gastric (6.8%), ovarian (11.3%), and primary peritoneal (7.5%). 
Key Points
Question Is intraoperative fluid management associated with morbidity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy?
Findings In this cohort study of 133 patients, intraoperative fluid rate was significantly associated with morbidity, with patients receiving more than 15.7 mL/kg/h experiencing a 43% increase in complications.
Meaning Fluid administration protocols that include standardized restrictive fluid rates can potentially help to mitigate morbidity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. patients. There were no mortalities at 30 days. The median hospital length of stay was 10.5 days (IQR, (8) (9) (10) (11) (12) (13) (14) (15) . Table 1 demonstrates other perioperative data and outcomes. On univariate analyses ( Table 2) , blood loss, urine output, IOF rate, number of organs resected, and peritoneal cancer index were significantly associated with CCI; age, chemotherapeutic perfusion agent, number of anastomoses, ASA classification, and sex were not associated with age. On multivariate analysis (Table 3) , age, IOF rate, and blood loss were independent predictors of increased CCI. In particular, when patients were stratified into 2 subgroups by the mean IOF rate of 15.7 mL/kg/h, those whose IOF rate was greater than or equal to 15.7 mL/kg/h developed a 43% increase in CCI compared with patients whose rate was lower than 15.7 mL/kg/h (31.5 vs 22.0, P = .02), despite both subgroups having a similar overall ASA classification (ASA 3: 55.3% vs 68.4%, P = .20) and age (mean, 53 vs 56 years, P = .46).
Because the association between intraoperative fluid administration and blood loss is close, we performed a separate multivariate analysis excluding patients in the highest quartile of blood loss (>1000 to 7000 mL). Using CCI again as the outcome variable, results are presented in Table 4 (n = 109). Blood loss was no longer an independent predictor of CCI; IOF rate was found to be the only independent predictor of increased CCI.
Discussion
Cytoreductive surgery with HIPEC presents a variety of hemodynamic considerations intraoperatively, because the surgeries can be lengthy and accompanied by significant blood loss and other insensible losses. Physiologic factors, such as body temperature, heart rate, central venous pressure, and pulmonary artery pressure, have been shown to increase during the chemotherapy perfusion. 22, 23 In observation of this hyperdynamic circulatory state, early observations recommended administration of liberal amounts of intravenous fluids to maintain an effective circulating volume, as high as 1781 mL/h.
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Several single-institutional studies have published retrospective data on their CRS/HIPEC experiences. Schmidt et al 24 descriptively reported on a series of 78 patients in whom a median IOF rate of 22.2 mL/kg/h was observed. Kajdi et al 25 analyzed a series of 54 patients, the majority of whom underwent CRS/HIPEC for appendiceal and colorectal cancers. Overall, patients received IOF at a rate of approximately 10 mL/kg/h. Complications were associated with greater operation length, anesthesia time, receipt of blood transfusions, and use of hydroxyethyl starch colloid solution. However, neither of these studies analyzed IOF administration rate in relation to perioperative outcomes. Approaches to perioperative fluid management in major abdominal surgery have undergone a transformation from traditionally liberal to more restrictive regimens. The impetus for this change in clinical practice is attributed to level I evidence demonstrating improvements in morbidity with perioperative fluid restriction. [7] [8] [9] Perioperative fluid restriction in the context of enhanced recovery after surgery pathways in colorectal surgery has been shown to mitigate complications, as well.
10,11
As an example, in 1 study randomizing patients receiving 5 to 7 mL/kg/h to 18 mL/kg/h of crystalloid intraoperatively, patients in the restricted fluid group experienced improved postoperative pulmonary function.
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However, challenges have arisen in the interpretation of the existing literature, since definitions of liberal and restrictive regimens are heterogeneous among studies. Moreover, these trials varied in their approach toward fluid restriction, whether it was intraoperative, postoperative, or both. 15, 16 Most of these studies were performed on patients undergoing elective colorectal surgery; subsequent trials attempting to extrapolate this concept to other forms of abdominal surgery have not shown a clear benefit with fluid restriction.
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In the context of no clear definition of liberal and restrictive fluid regimens, goal-directed fluid therapy has been investigated in the context of major abdominal surgery and offers an approach that provides intraoperative fluid administration based on physiologic factors. Several randomized trials in elective colorectal resection have shown goal-directed fluid therapy to be associated with decreased morbidity, length of stay, and earlier toleration of a diet. [12] [13] [14] Given the physiologic variability during CRS/HIPEC procedures, goal-directed therapy would seem to be a potentially beneficial approach in these patients. As such, Colantonio et al 27 recently published a single-center, prospective, randomized study in which patients undergoing CRS/HIPEC were randomized to goal-directed (n = 38) and standard (n = 42) fluid therapy arms, with the primary end point being the occurrence rate of abdominal complications. Patients in the control group received crystalloid infusions from 4 to 10 mL/kg/h, while patients in the goal-directed therapy group received a baseline rate of 4 mL/kg/h and subsequent colloid boluses based on physiologic variables. Those authors found that patients in the goal-directed therapy group experienced fewer abdominal complications and shorter lengths of stay. 27 Although the findings of this study demonstrate benefits of goal-directed therapy, criticisms include the routine use of plasma administration and its effect on the fluid protocols. 28 In addition, the baseline fluid rate range in the control group was heterogeneous, with perhaps a significant portion of patients in the control group experiencing relatively restrictive fluid regimens. Nevertheless, the Colantonio et al 27 study
was the first to demonstrate a role for goal-directed fluid therapy in patients undergoing CRS/HIPEC. Our study demonstrates an association between intraoperative fluid administration and perioperative morbidity in a large cohort of patients undergoing CRS/HIPEC. Given the physiologic demands of CRS/HIPEC, these patients are susceptible to the deleterious effects of fluid overload. Because patients undergoing CRS/HIPEC can experience multiple perioperative complications, sometimes involving several organ systems, CCI allowed us to assess cumulative morbidity as a continuous variable.
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Limitations
Limitations of our study include its retrospective design, which prevents us from determining a causal association between fluid administration and morbidity. We were also not able to assess an association with fluid administration and mortality, since our 30-day mortality rate was zero. Perioperative variables closely related to fluid administration, such as blood loss, can affect the amount of fluids that a patient receives, and we attempted to account for this with an interaction term in the multivariate analysis as well as performing a separate analysis omitting patients in the highest quartile of blood loss.
Conclusions
Increased intraoperative fluid administration is associated with a significant increase in perioperative morbidity in patients undergoing CRS/HIPEC, particularly in patients who receive intraoperative fluids at 15.7 mL/kg/h or more. Fluid administration protocols that include standardized restrictive fluid rates can potentially help to mitigate morbidity in patients undergoing CRS/HIPEC and further explain the association between fluid administration and morbidity in patients undergoing CRS/HIPEC. Peritoneal cancer index 0.51 (−0.14 to 1.15) .12
Urine output, mL 0.00 (−0.01 to 0.00) .84
Abbreviation: CCI, comprehensive complication index. 
